肺黏液表皮样癌( Primary pulmonary mucoepidermoid car-cinoma,PMEC)是一种罕见的唾液腺型肿瘤,占所有肺部恶性肿瘤的0.1％～0.2％[1].PMEC现在被定义为以鳞状细胞、黏液分泌细胞和中间细胞类型组合为特征的肿瘤,通常根据组织学外观、有丝分裂活性、细胞异型性、局部浸润分为低级别和高级别[2].由于该病罕见,临床症状不典型,关于其人口统计学、治疗、预后和生存率知之甚少.本文介绍1名老年女性PMEC患者并文献复习,以提高对该病的认识.

食管癌是一种在全世界范围内常见的恶性肿瘤.由于食管癌缺乏特异性的肿瘤标志物,难以及时有效地监测肿瘤的发生发展、耐药的发生及有效的评估预后,致使临床治疗效果不佳.许多研究表明,长链非编码RNA(lncRNA)是功能基因组元件,可以在多个水平上发挥作用.近年来发现多种lncRNA在食管癌中异常表达,这些异常表达的lncRNA在食管癌发生发展的过程中发挥促癌或抑癌作用,并与食管癌的治疗耐药、预后等密切相关,lncRNA有望成为新的诊断或治疗的生物靶点.

目的:运用生物信息学技术分析淋巴增强因子-1(Lymphoid enhancer factor-1,LEF1)在胃癌中的表达及意义.方法:通过Oncomine、Ualcan、肿瘤免疫评估资源(TIMER)数据库检索并分析LEF1基因在胃癌中的表达.TIMER数据库分析LEF1在免疫浸润物中的表达;Ualcan数据库、Kaplan-Meier Plotter分析LEF1表达与患者生存及预后相关性.结果:Oncomine、TIMER、Ualcan数据库中均显示LEF1在胃癌中高表达,Kaplan-Meier Plotter分析得出LEF1高表达的胃癌患者无疾病生存时间、总生存时间较短(P<0.05);TIMER数据库分析显示在免疫微环境中高表达LEF1 mRNA巨噬细胞的胃癌患者5年生存预后较好,LEF1 mRNA在胃癌免疫微环境中的表达与多种免疫细胞在胃癌组织的免疫微环境中的表达明显相关.结论:LEF1在胃癌中表达增加,与胃癌患者不良预后相关,是胃癌预后的潜在的评判指标.

信号淋巴细胞活化分子受体(SLAMF)表达于众多免疫细胞中,通过共刺激参与免疫调节,在自身免疫性疾病、感染性疾病、造血系统疾病及恶性肿瘤中发挥重要作用,其通过调节肿瘤微环境及免疫细胞的功能,最终影响着免疫细胞的抗肿瘤作用.SLAMF在正常组织与肿瘤组织中的表达差异使其具有作为肿瘤诊断标志物的潜力,肿瘤免疫抑制剂通过逆转免疫检查点途径相关的"免疫逃逸"来使得肿瘤患者获益,其中许多抑制剂已在临床恶性肿瘤治疗中取得良好疗效,但仍有部分患者无法从中获益,寻求新的免疫治疗靶点已成为当下热门话题.本文将对SLAMF的作用机制及其在诊断与治疗中的研究进展进行综述.

目的 探讨色素上皮衍生因子(PEDF)联合顺铂(DDP)对卵巢癌细胞的抑制作用以及对卵巢癌小鼠的治疗效果.方法 体外培养ID8细胞株,将细胞分为对照组、PEDF组和PEDF+DDP组,分别加入PBS、PEDF和PEDF+DDP处理ID8细胞.通过细胞划痕实验和CCK-8实验观察每组细胞迁移和增殖.随后,建立C57BL/6小鼠卵巢癌模型,将24只卵巢癌模型小鼠随机分为模型组、PEDF组和PEDF+DDP组,每组8只.模型组给予100μl PBS,PEDF组给予静脉注射12.5 mg/kg的PEDF蛋白,PEDF+DDP组给予静脉注射12.5 mg/kg PEDF蛋白和腹腔注射2 mg/kg顺铂注射液.隔日给药,共给药3次,20 d后处死小鼠并解剖分离肿瘤,检测肿瘤的体积,通过免疫组化和免疫荧光对肿瘤组织内的新生血管CD31的表达和凋亡细胞进行评价.结果 体外细胞实验表明,与对照组相比,PEDF组和PEDF+DDP组ID8细胞的迁移和增殖均显著降低(P<0.05);与PEDF组相比,PEDF+DDP组ID8细胞的迁移和增殖显著降低(P<0.05).动物体内实验表明,与模型组相比,PEDF组和PEDF+DDP组肿瘤体积的增长速率明显放缓(P<0.05);与PEDF组相比,PEDF+DDP组肿瘤体积的增长速率明显放缓(P<0.05).与模型组相比,PEDF组和PEDF+DDP组小鼠肿瘤组织中CD31的表达明显下调,而肿瘤细胞的凋亡率明显升高(P<0.05);与PEDF组相比,PEDF+DDP组CD31的表达明显下调,而肿瘤细胞的凋亡率明显提高(P<0.05).结论 PEDF和DDP联合用药对卵巢癌细胞具有协同抑制作用以及对卵巢癌小鼠模型具有协同治疗作用.这种协同治疗效果优于PEDF单独治疗的效果.

目的 通过观察磷脂酰肌醇3-激酶(PI3K)特异性抑制剂LY294002在成骨细胞分化过程中的影响,探讨PI3K通过调控PDK-1 /Akt信号通路对成骨细胞分化影响的分子机制.方法 采用体外培养C57BL/6小鼠骨髓间充质干细胞(BMSC).通过CCK-8检测LY294002的最大安全浓度.对照组使用成骨细胞诱导培养基(OBM)处理BM-SC,干预组在OBM中添加LY294002.检测两组细胞碱性磷酸酶(ALP)活性和细胞矿化能力,并分别采用Western-Blot和RT-PCR检测PDK-1/Akt信号通路及下游蛋白和转录因子基因的表达水平.结果 CCK-8结果提示,在3.2μM及以下浓度对BMSC的增殖没有影响;LY294002对成骨细胞分化的影响呈剂量依赖性(P＜0.05);干预组ALP阳性细胞和细胞外基质矿化较对照组明显减少(P＜0.05);Western-Blot检测结果显示,干预组p-PDK-1和p-Akt蛋白表达水平较对照组明显降低(P＜0.05);RT-PCR结果提示,干预组成骨细胞相关基因ALP和骨钙素(OCN)mRNA较对照组表达明显下降(P＜0.05).结论 靶向抑制PI3K可通过PDK-1 /Akt信号通路明显下调成骨细胞相关基因ALP和OCN的表达,并抑制成骨细胞的分化.

目的 对低剂量螺旋CT(LDCT)用于高危人群肺癌筛查进行卫生经济学评价,探讨在中国开展LDCT肺癌筛查的适宜年龄.方法 基于2018年在四川省开展的肺癌筛查及早诊早治项目,运用TreeAgePro2011构建Markov模型,模拟肺癌筛查诊治过程,进行LDCT筛查策略下的卫生经济学效果评价.模型参数来自于四川省肺癌筛查及早诊早治项目和文献资料.结果 与未筛查组进行比较,筛查起始年龄为50、55、60、65和70岁的筛查方案挽救的生命年分别为1977.60、2 211.37、2483.34、2 336.90和425.23年/10万人,其中60岁组最高.与未筛查组进行比较,各个年龄段开始筛查均符合成本效果原则,其中筛查年龄为50岁组的筛查方案每挽救1个生命年的所需成本最高,增量成本效果比为2 397.94元/年;筛查年龄为70～74岁组的筛查方案每挽救1个生命年的成本低于未筛查组,增量成本效果比为-86.49元/年.60岁组和65岁组的筛查方案具有优势,其增量成本效果比依次为6482.13和517.62元/年,65岁组中筛查方案多挽救1个生命年所需的增量成本相对更低.与未筛查组相比较,各个年龄段的筛查方案使肺癌的发病和死亡风险分别降低24％和21％以上.结论 1年1次的LDCT检查在各筛查年龄组均符合成本效果原则,但筛查年龄为60岁组和65岁组方案更具有优势.

目的:研究相对电子密度对术后宫颈癌放射治疗计划剂量准确度的影响.方法:选取4例实施术后宫颈癌放射治疗计划的患者,在计划系统中赋予膀胱相对电子密度(rED)分别为1.027、0.5,和1.5,在保持原通量优化的前提下重新进行剂量计算,生成的新计划命名为Plan1、Plan2和Plan3.统计靶区计划临床靶体积(PCTV)阴道残端(PCTV1)、宫旁组织(PCTV2)和淋巴结引流区(PCTVln)的剂量参数中98％、2％靶区体积对应的绝对剂量(D98、D2)和平均剂量(Dmean),危及器官(OAR)膀胱、直肠及小肠在剂量体积直方图中的1 cc体积所受照剂量(D1cc)、Dmean和容积剂量(V30、V40)参数,以及子野总数﹑计划总跳数(MU).比较剂量参数与原始计划(Plan0)的相对偏差.结果:Plan1中PCTV1、PCTV2及PCTVln的剂量参数D98、D2及Dmean与原始计划的平均相对偏差为-0.2％、-0.03％和0.04％,Plan2中3个靶区的剂量参数与原始计划的平均相对偏差在1.7％、0.4％和0.5％以内,Plan3产生的偏差最为明显,分别为-5％、2％和1.5％.Plan1中膀胱、直肠及小肠的D1cc、Dmean、V30和V40与原始计划的平均偏差分别为-0.5％、-0.2％和0.1％,Plan2、Plan3的剂量影响是Plan1的5倍以上.同一患者的计划子野总数不变,跳数有所变化,Plan1、Plan2和Plan3与Plan0的平均跳数偏差分别为0.05％、-0.47％和1.84％.结论:对于术后宫颈癌,将准确的相对电子密度赋予计划系统后可以生成临床上使用的放射治疗计划,而对于其他部位的肿瘤治疗计划还需进一步研究.

免疫治疗是现今肿瘤治疗的重要方式,其中程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂是目前应用较为成熟且患者生存获益较大的免疫制剂.程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂给食管癌患者带来更好的临床获益,也为食管癌的治疗提供了更有利的选择.该文介绍了程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂的作用机制、在食管癌中的应用以及疗效预测指标,旨在为程序性死亡蛋白-1/程序性死亡蛋白配体-1抑制剂更合理地用于食管癌提供一定理论基础.

目的 探讨miRNA-675-5p表达水平与食管鳞癌(ESCC)上皮间质转化(EMT)的相关性.方法 采用实时定量PCR技术检测miRNA-675-5p在ESCC组织及配对癌旁正常组织中的表达差异,并分析其表达水平与患者临床分期的相关性.脂质体转染ECA109细胞,分为miR-675-recursor组、miR-675-5p-inhibition组和NC组,上调及抑制miRNA-675-5p表达水平,分析改变目的基因表达后对ECA109细胞株迁移侵袭能力的影响,蛋白印迹实验检测干扰表达每组细胞中EMT相关蛋白E-cadherin、N-cadherin、Vimentin表达水平,评估其对ECA 109株EMT过程的影响.结果 与癌旁正常组织比较,miRNA-675-5p在ESCC组织中表达显著升高(P＜0.05),不同分期患者miRNA-675-5p表达比较,差异有统计学意义(P＜0.05).与NC组比较,miR-675-recursor组细胞迁移侵袭能力明显增强,miR-675-5p-inhibition组细胞迁移侵袭能力受到显著抑制(P＜0.05).此外,与NC组比较,miR-675-recursor组E-cadherin蛋白表达降低,N-cadherin、Vimentin蛋白表达升高;miR-675-5p-inhibition组E-cadherin蛋白表达升高,N-cadherin、Vimentin蛋白表达降低(P＜0.05).结论 miRNA-675-5p表达与ESCC患者TNM分期相关,miR-675-5p能促进ESCC细胞间质转化从而增强侵袭能力;下调表达能逆转ESCC细胞EMT过程,降低迁移侵袭能力.

环状RNA(circRNA)是一类非编码RNA,广泛存在于生物体中,具有结构稳定、半衰期长、高度保守性及特异性表达等生物学特性.circRNA具有充当miRNA海绵、调控基因转录、参与蛋白质翻译等功能.circRNA在乳腺癌、肺癌、结直肠癌、食管癌等肿瘤中均有表达,且与肿瘤的发生发展以及预后密切相关,未来circRNA在肿瘤早筛查、肿瘤治疗等领域具有巨大潜力.

目的:观察蛋白激酶B(Akt)特异性抑制剂MK2206对成骨细胞分化的影响,探讨PI3K/Akt信号通路影响成骨细胞分化的分子机制.方法:通过CCK-8检测MK2206对骨髓间充质干细胞(BMSC)增殖的最大安全浓度;将BMSC分为两组,其中对照组使用OBM诱导处理,干预组加入含有3μmol/L的MK2206的OBM进行诱导处理,检测细胞碱性磷酸酶(ALP)活性和矿化能力,实时荧光定量PCR(qPCR)检测相关基因的表达水平.将细胞分为3组,其中OBM组仅加入成骨细胞诱导培养基培养;OBM+MK2206组使用含有3 μmol/L MK2206的OBM培养;MK2206组中使用含有3 μmol/L MK2206的普通培养基处理,采用Western blotting检测相关蛋白的表达情况.结果:CCK-8结果提示,在3.2 μmol/L及以下浓度MK2206对BMSC的增殖没有影响;随着浓度的升高,ALP阳性的细胞数量逐渐下降;干预组的ALP表达、细胞外基质矿化能力、ALPmRNA和骨钙素(OCN)mRNA表达较对照组均明显减少(均P<0.05);与OBM组比较,OBM+MK2206组和MK2206组细胞中RUNX2、CollagenⅠ和p-Akt蛋白均出现明显的降低,且MK2206组下降更加明显(均P<0.05).结论:靶向抑制Akt在体外细胞培养中可通过PI3K/Akt信号通路明显下调成骨细胞相关基因ALP和OCN的表达,并抑制成骨细胞的分化成熟.

目的:探讨影响老年弥漫大B细胞淋巴瘤治疗与预后的相关因素.方法:选取我院肿瘤科2008年7月至2014年7月收治的20例年龄大于65岁的弥漫大B细胞淋巴瘤病人,观察影响疗效及总生存率的各种变量,分析导致死亡的最主要因素.结果:16例病人接受治疗,4例病人未接受治疗.接受治疗的16例病人2年生存率为40％,中位生存时间为15个月.其中分期早、白蛋白高、IPI值2分以下、完成治疗的病人2年生存率高、预后好.利用COX比例风险回归模型分析感染、有无完成治疗是影响患者总生存期的因素.结论:感染是导致生存率下降的危险因素,也是导致死亡最主要的因素.

Objective To evaluate the effect of radiotherapy on mediastinal metastasis from esophageal carcinoma after surgery.Methods From 2010 to 2014,47 patients were treated with postoperative irradiation.Among them,there were 37 males and 10 females,aged 38 to 80 years.The lesion was located in 5 cases of the upper chest,40 cases in the chest and 2 in the lower chest.The postoperative stage] was 29 cases and stageⅢ was 18 cases.47 cases of postoperative pathological diagnosis were squamous cell carcinomas.There were 31 cases of pure radiotherapy and 16 cases of chemotherapy.Results The survival rates of 1,2 and 3 years after treatment were 58.1％,36％ and 19.4％,respectively.Single factor analysis showed that the preoperative site,radiotherapy dose and postoperative stage had significant effect on prognosis (P＜ 0.05).The patient's sex,tumor length,radiotherapy and chemotherapy were not related to the prognosis.COX regression analysis showed that the postoperative stage and radiation dose were independent prognostic factors (P＜0.05).Conclusion The dose of esophageal lesion and radiotherapy is the main prognostic factor of the metastatic lymph node metastasis after esophageal carcinoma.

目的 探讨小剂量奥氮平在胃癌根治术后辅助性同步放化疗所致恶心呕吐的疗效观察.方法 选取2015年7月至2017年2月间南充市中心医院收治的48例胃癌术后患者,采用随机数表法分为治疗组和对照组,每组24例.两组患者均采用顺铂同步放化疗,化疗前用托烷司琼和地塞米松,且治疗组自化疗当天口服奥氮平,比较两组患者放化疗期间恶心呕吐发生情况.结果 治疗组患者中无恶心呕吐反应的比例多于对照组,出现Ⅰ～Ⅲ度的比例少于对照组,差异均有统计学意义(均P＜0.05).结论 奥氮平联合托烷司琼和地塞米松,对预防、控制胃癌根治术后顺铂同步放化疗所致急性恶心呕吐和延迟性恶心呕吐的效果较佳,值得临床推广.

Objective To observe the efficacy of hyperthermia combined with gemcitabine for platinum-resistance epithelial ovarian cancer.Methods A total of 50 patients with epithelial ovarian cancer who had platinum-resistance and relapsed within 6 months after the chemotherapy were selected.Using a random number table,patients were divided into an experimental and a control group with 25 patients in each group.Experimental group was given BSD2000 hyperthermia combined with gemcitabine chemotherapy and the control group was only given gemcitabine chemotherapy.Results RR were 30.0％ for the experimental group and 20.0％ for the control group (P ＞ 0.05).PCR rate was 68.0％ for the experimental group and 40％ for the control group (P ＜ 0.05).The ratio of CD3 +,CD4 +,CD8 +,and CD3 + + CD56 + increased compared with the control group (P ＜ 0.05).Adverse reaction rates were similar between the two groups (P ＞ 0.05).Conclusion In this study,hyperthermia combined with gemcitabine is efficient and safe for platinum-resistance epithelial ovarian cancer and is worthy of clinical application.

Objective: To evaluate the survival of patients with locally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy compared with concurrent chemoradiotherapy alone.Methods: Seven databases were searched,including the Cochrane Library(Issue 2,2016),Pubmed,Embase,CBM,CNKI,VIP and Wanfang Database.The methodological quality assessment of eligible researches was conducted according to the Jadad scale and The Newcastal-Ottawa Scale.The Meta-analysis was performed by the Revman 5.3 software.Results: Eleven researches containing 1 521 patients were finally included.The 5-year distant metastasis-free survival of patients treated with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy was significantly higher than that of those treated with concurrent chemoradiotherapy alone.There were no significant difference in 3-year overall survival,3-year distant metastasis-free survival,3-year progression-free survival,3-year recurrence free survival,5-year overall survival,5-year progression-free survival and 5-year recurrence free survival (P>0.05) respectively between these two regimens.Conclusion: Current evidence shows that compared with concurrent chemoradiotherapy alone,neoadjuvant chemotherapy followed by concurrent chemoradiotherapy could improve distant metastasis-free survival in locally advanced nasopharyngeal carcinoma,while no difference was found of the total survival between these two regimens.

Objective To understand the adverse reactions of Kanglaite injection and its incidence and explore the factors affecting the safety of Kanglaite Injection in clinical use. Methods A non-interventional and prospective hospital based monitoring study and nested case-control study were conducted. All hospitalized cancer patients receiving Kanglaite injections from 28 hospitals in northeast, north, central, east, south, southwest, northwest regions of China from September 2013 to September 2014 were enrolled in this study. The main monitoring contents included the general status of patients, the drug administration (including indications and combined use), medication safety, and so on. Patients developing adverse reactions related to Kanglaite injection distributed in the case group and patients who did not develop adverse reactions were randomly selected and distributed into the control group with a ratio of 1 ∶ 3, and the factors that affect the safe use of Kanglaite injection were analyzed. Results A total of 5 022 cancer patients were entered into the study, including 2 926 males and 2 096 females with age from 9 to 95 years and their average age was (60±12) years. The top five tumors were lung cancer (1 456 patients, 28.99%), intestinal cancer (867 patients, 17.26%), mammary cancer (372 patients, 7.41%), gastric cancer (346 patients, 6.89%), and liver cancer (335 cases, 6.67%). There were 3 863 patients (76.92%) with tumor stage III and IV, 348 patients with allergic history (6.93%); 2 524 patients were complicated with other diseases (50.26%); 4 687 patients (93.33%) had combined drug therapy. During the monitoring period, 751 (14.95%) of 5 022 patients developed adverse events and of them, 18 cases met the criteria of causality of adverse reactions, including 7 cases of phlebitis, 3 cases of nausea and vomiting, 3 cases of chills, 2 cases of rash, 1 case of palpitation, 1 case of transaminase increase, and 1 case of fever. The incidence of adverse reactions was 0.36%. Univariate analysis showed that the incidence of adverse reactions in patients with combined diseases was higher than that in patients without combined diseases (χ2=5.4723, P=0.019), the incidence of adverse reactions in patients with combined western medication was higher than that in patients with combined western and Chinese medication(P=0.002). Logistic regression analysis showed that the influencing factors of adverse reactions were coexisting diseases (OR=1.636, 95%CI: 1.100-2.433, P=0.013) and combined medication (OR=1.475, 95%CI: 1.108-1.965, P=0.027). Nested case-control study showed that the influencing factors of adverse reactions induced by Kanglaite injection were radiotherapy (OR=1.864, 95%CI: 0.930-3.736, P<0.01) and combined medication (OR=1.622, 95%CI: 1.102-2.389, P<0.01). Conclusions The incidence of adverse reactions of Kanglaite injection in clinical application is lower and the safety is good. Coexisting diseases, combined medication and radiotherapy are main factors affecting its clinical safety. Key words: Kanglaite injection; Safety; Evaluation studies

To understand the adverse reactions of Kan,glaite injection and its incidence and explore the factors affecting the safety of Kan,glaite Injection in clinical use.Methods A noninterventional and prospective hospital based monitoring study and nested case-control study were conducted.All hospitalized cancer patients receiving Kan.glaite injections from 28 hospitals in northeast, north, central,east, south, southwest, northwest regions of China from September 2013 to September 2014 were enrolled in this study. The main monitoring contents included the general status of patients, the drug administration (including indications and combined use), medication safety, and so on. Patients developing adverse reactions related to Kan,glaite injection distributed in the case group and patients who did not develop adverse reactions were randomly selected and distributed into the control group with a ratio of l : 3 , and the factors that affect the safe use of Kan,glaite injection were analyzed.Results A total of 5 022 cancer patients were entered into the study, including 2 926 males and 2 096 females with age from 9 t0 95 years and their average age was (60 + 12) years. The top five tumors were lung cancer (1 456 patients,28.99%) ,intestinal cancer (867 patients,17.26% ) , marmuary cancer ( 372 patients, 7.41% ) , gastric cancer ( 346 patients, 6.89%) , and liver cancer (335 cases,6.67%). There were 3 863 patients (76.92% ) with tumor stage III and IV, 348 patients with allergic history (6.93%) ; 2 524 patients were complicated with other diseases (50.26% ) ; 4 687 patients (93.33%) had combined drug therapy.During the monitoring period,751(14.95%) of 5 022 patients developed adverse events and of them, 18 cases met the criteria of causality of adverse reactions, including 7 cases of phlebitis, 3 cases of nausea and vomiting, 3 cases of chills, 2 cases of rash, 1 case of palpitation, 1 case of transammase increase, and l case of fever. The incidence of adverse reactions was 0.36%. Univariate analysis showed that the incidence of adverse reactions in patients with combined diseases was higher than that in patients without combined diseases (X2=5.4723,P=0.019),the incidence of adverse reactions in patients with combined western medication was higher than that in patients with combined westem and Chinese medication (P=0.002).Logistic regression analysis showed that the influencing factors of adverse reactions were coexisting diseases (OR=1. 636, 95%C/:1.100-2.433,P= 0.013)and combined medication (OR=1.475,95%C/:1.108-1.965,P=0.027).Nested case-control study showed that the influencing factors of adverse reactions induced by Kan.glaite injection were radiotherapy (OR= 1.864,95% C/:0.930-3.736,P<0.01)and corubined medication (OR=1.622,95% C/:1.102-2.389,P<0.01) .Conclusions The incidence of adverse reactions of Kan,glaite injection in clinical application is lower and the safety is good. Coexisting diseases, combined medication and radiotherapy are main factors affecting its clinical safety.

Objective To observe the efficacy of BSD2000 deep regional hyperthermia combined with Topotecan chemotherapy on epithelial ovarian cancer with platinum-resistance. Methods Total of 60 patients were divided into experimental and control groups, experimental group was treated with BSD2000 hyperthermia with Topotecan chemotherapy,and the control group was only treated with Topotecan chemotherapy. Results The RR of observation group and the control group were 36.7% and 23.3%,the two groups had no statistically significant difference(P>0.05);DCR were 70% and 40%,there was significant difference between two groups(P<0.05);CD3+,CD4+,CD8+,CD3+CD56+double positive cells ratio in the observation group after treatment were higher than the control group (P<0.05);two groups of similar adverse reactions. Conclusions In this study,Hyperthermia combined with Topotecan chemotherapy on epithelial ovarian cancer with platinum -Resistance is effective and safe,and is worthy of clinical application.